These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 10916207

  • 1. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
    Spicka I, Cieslar P, Procházka B, Jirsa M, Chrz M, Gregora E, Klener P.
    Cas Lek Cesk; 2000 Apr 12; 139(7):208-12. PubMed ID: 10916207
    [Abstract] [Full Text] [Related]

  • 2. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM.
    Cancer; 2003 May 15; 97(10):2440-52. PubMed ID: 12733143
    [Abstract] [Full Text] [Related]

  • 3. [Monitoring markers of bone turnover in multiple myeloma].
    Spicka I, Spacek P, Hulejová H, Procházka B, Cieslar P, Chrz M, Válková V, Klener P.
    Vnitr Lek; 1999 Aug 15; 45(8):463-7. PubMed ID: 11045145
    [Abstract] [Full Text] [Related]

  • 4. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
    Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A.
    Cancer; 1998 May 15; 82(10):1860-6. PubMed ID: 9587117
    [Abstract] [Full Text] [Related]

  • 5. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H, Wiersbowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2000 Sep 15; 11(3):443-51. PubMed ID: 11022130
    [Abstract] [Full Text] [Related]

  • 6. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V, Zemanova M, Minarik J, Bacovsky J, Ordeltova M, Indrak K, Budikova M, Dusek L, Farbiakova V.
    Neoplasma; 2006 Sep 15; 53(4):277-84. PubMed ID: 16830053
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG, Passam FH, Kyriakou DS, Christophoridou AV, Perisinakis K, Hatzivasili A, Foudoulakis A, Castanas E.
    Am J Hematol; 2004 Feb 15; 75(2):101-6. PubMed ID: 14755377
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV, Andreeva NE, Izgorodin AS.
    Ter Arkh; 1995 Feb 15; 67(7):35-9. PubMed ID: 7482303
    [Abstract] [Full Text] [Related]

  • 12. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA.
    Eur J Haematol; 2004 Apr 15; 72(4):252-8. PubMed ID: 15089762
    [Abstract] [Full Text] [Related]

  • 13. [Multiple myeloma--diagnosis, prognostic factors and treatment].
    Kitani T.
    Rinsho Ketsueki; 1995 May 15; 36(5):471-9. PubMed ID: 7783353
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, Uike N, Umemura T, Nawata H, Nishimura J.
    Cancer; 2002 Apr 15; 94(8):2232-8. PubMed ID: 12001122
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.
    Haematologica; 2008 Apr 15; 93(4):560-5. PubMed ID: 18322252
    [Abstract] [Full Text] [Related]

  • 18. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Scudla V, Budíková M, Pika T, Bacovský J, Minarík J, Heinzová V, Langová K.
    Cas Lek Cesk; 2009 Apr 15; 148(7):315-22. PubMed ID: 19642297
    [Abstract] [Full Text] [Related]

  • 19. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V, Budíková M, Bacovský J, Opíchalová D, Farbiaková V.
    Cas Lek Cesk; 2000 Jul 05; 139(13):401-6. PubMed ID: 10971970
    [Abstract] [Full Text] [Related]

  • 20. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J.
    Ai Zheng; 2006 Apr 05; 25(4):461-4. PubMed ID: 16613681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.